Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Clin Pharmacol Ther. 2022 May 2;112(1):146–155. doi: 10.1002/cpt.2612

Figure 2. Time-to-Event Curve for Major Atherothrombotic Events Stratified by ABCD-GENE Score and CYP2C19 IM Status.

Figure 2.

Major atherothrombotic events (MAE), defined as the first occurrence of death, myocardial infarction, ischemic stroke, stent thrombosis, or unstable angina requiring revascularization at 1-year post-PCI. Adjusted hazard ratio (HR) for ABCD-GENE score <10-Non-IM versus ≥10 = 0.58 (95% CI, 0.43–0.79), p<0.001. Adjusted HR for ABCD-GENE score <10-IM versus ≥10 = 1.03 (95% CI, 0.59–1.81), p=0.917. IM: CYP2C19 intermediate metabolizer. The tails of the Kaplan-Meier curve were truncated at 360 days post-PCI, after which time less than 10% of each stratum were available for follow-up. In the ABCD-GENE <10-Non-IM group, n=4 events were observed after day 360, when only 64 patients (4%) were still in follow-up. No MAE occurred after day 360 for the ABCD-GENE score ≥10 or score <10-IM groups when 16 (3%) and 7 (4%) patients were available for follow-up, respectively.